AF
PTGX icon

Allworth Financial’s Protagonist Therapeutics PTGX Stock Holding History

Allworth Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-313
Closed -$33K – 5349
2026
Q1 		$33K Buy
+313
New +$27.7K ﹤0.01% 2628
2025
Q4 		– Sell
-247
Closed -$16.4K – 5234
2025
Q3 		$16.4K Buy
247
+130
+111% +$7.39K ﹤0.01% 2827
2025
Q2 		$6.47K Buy
117
+87
+290% +$4.17K ﹤0.01% 3127
2025
Q1 		$1.35K Buy
+30
New +$1.26K ﹤0.01% 3364

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allworth Financial's PTGX Position: Q2 2026 in Review

Allworth Financial sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 313 shares — an estimated $33K sold.

Allworth Financial first reported a position in PTGX in Q1 2025 and held it in 4 quarters. The position peaked at $33K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Allworth Financial reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Allworth Financial sold 313 Protagonist Therapeutics shares in Q2 2026, an estimated $33K.
  • Allworth Financial first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 4 quarters.
  • Allworth Financial's Protagonist Therapeutics position peaked at $33K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.